{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+B&page=13", "query": { "intervention": "Dose B", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 6946, "total_pages": 695, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+B&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+B&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T01:53:14.699Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03835533", "title": "Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "NKTR-214 (Cohort A)", "type": "DRUG" }, { "name": "Nivolumab (Cohort A, B and C)", "type": "DRUG" }, { "name": "Stereotactic body radiation therapy (SBRT) (Cohort B)", "type": "RADIATION" }, { "name": "CDX-301 (Cohort B and C)", "type": "DRUG" }, { "name": "Poly-ICLC (Cohort B)", "type": "DRUG" }, { "name": "INO-5151 (Cohort C)", "type": "DRUG" }, { "name": "Cellectra 2000", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "RADIATION", "DEVICE" ], "sponsor": "Parker Institute for Cancer Immunotherapy", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 43, "start_date": "2019-06-21", "completion_date": "2022-10-03", "has_results": true, "last_update_posted_date": "2024-04-12", "last_synced_at": "2026-10-20T01:53:14.699Z", "location_count": 6, "location_summary": "Los Angeles, California • San Francisco, California • New York, New York + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03835533" }, { "nct_id": "NCT03905148", "title": "Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "Lifirafenib", "type": "DRUG" }, { "name": "mirdametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 91, "start_date": "2019-05-01", "completion_date": "2025-10-23", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-10-20T01:53:14.699Z", "location_count": 2, "location_summary": "Santa Monica, California • Houston, Texas", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03905148" }, { "nct_id": "NCT02234934", "title": "Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Granulomatous Disease, Chronic, X-linked" ], "interventions": [ { "name": "Lentiviral G1XCGD Gene Therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "23 Months", "maximum_age": null, "sex": "MALE", "summary": "23 Months and older · Male only" }, "enrollment_count": 10, "start_date": "2015-10-29", "completion_date": "2024-12-01", "has_results": false, "last_update_posted_date": "2025-05-02", "last_synced_at": "2026-10-20T01:53:14.699Z", "location_count": 3, "location_summary": "Los Angeles, California • Bethesda, Maryland • Boston, Massachusetts", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02234934" }, { "nct_id": "NCT07871214", "title": "A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Early-Stage Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Pumitamig", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2026-11-30", "completion_date": "2028-03-15", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-20T01:53:14.699Z", "location_count": 9, "location_summary": "Long Beach, California • Los Angeles, California • Tampa, Florida + 6 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chestnut Hill", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07871214" }, { "nct_id": "NCT06872333", "title": "Allo HSCT for High Risk Hemoglobinopathies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft Failure", "Sickle Cell Disease", "Hemoglobinopathies" ], "interventions": [ { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "Cell Infusion", "type": "BIOLOGICAL" }, { "name": "Thymoglobulin", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Plerixafor (mozobil)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": "55 Years", "sex": "ALL", "summary": "Up to 55 Years" }, "enrollment_count": 62, "start_date": "2024-11-19", "completion_date": "2032-06-01", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-20T01:53:14.699Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06872333" }, { "nct_id": "NCT06299709", "title": "A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VNZ/TEZ/D-IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 34, "start_date": "2024-03-13", "completion_date": "2024-05-23", "has_results": false, "last_update_posted_date": "2025-09-26", "last_synced_at": "2026-10-20T01:53:14.699Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06299709" }, { "nct_id": "NCT00333398", "title": "Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "CSL Trivalent Inactivated Influenza Vaccine - Thimerosal-free", "type": "BIOLOGICAL" }, { "name": "CSL Trivalent Inactivated Influenza Vaccine with Thimerosal", "type": "BIOLOGICAL" }, { "name": "Placebo with Thimerosal", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 1359, "start_date": "2006-06", "completion_date": "2006-08", "has_results": false, "last_update_posted_date": "2010-08-27", "last_synced_at": "2026-10-20T01:53:14.699Z", "location_count": 10, "location_summary": "Stanford, California • Iowa City, Iowa • Baltimore, Maryland + 7 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00333398" }, { "nct_id": "NCT02431793", "title": "EHR-Based Medication Complete Communication Strategy to Promote Safe Opioid Use", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Opioid Use, Unspecified" ], "interventions": [ { "name": "EMC2 Strategy", "type": "BEHAVIORAL" }, { "name": "SMS Text Reminders", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 652, "start_date": "2015-07", "completion_date": "2018-09", "has_results": true, "last_update_posted_date": "2019-09-25", "last_synced_at": "2026-10-20T01:53:14.699Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02431793" }, { "nct_id": "NCT06691906", "title": "A Clinical Study of Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-025)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Enlicitide decanoate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "19 Years to 55 Years" }, "enrollment_count": 40, "start_date": "2024-03-18", "completion_date": "2024-05-01", "has_results": false, "last_update_posted_date": "2024-11-18", "last_synced_at": "2026-10-20T01:53:14.699Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06691906" }, { "nct_id": "NCT01362452", "title": "Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "T-Cell Infusion", "type": "GENETIC" }, { "name": "Cord Blood Infusion", "type": "PROCEDURE" } ], "intervention_types": [ "GENETIC", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "75 Years", "sex": "ALL", "summary": "1 Year to 75 Years" }, "enrollment_count": 5, "start_date": "2012-12-07", "completion_date": "2017-07-25", "has_results": false, "last_update_posted_date": "2017-08-03", "last_synced_at": "2026-10-20T01:53:14.699Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01362452" } ] }